|
|
 |
|
Viewing report
|
|
|
|
China Company Report -- Hualan Biological Engineering Inc
China Market Report, June 2008, Pages: 14
Hualan Biological Engineering Inc is a leading Chinese blood products manufacturer, which possesses the widest varieties and complete in specifications of the whole blood products range and its capability of plasma processing is leading in domestic and even in Asia.
In 2007, Hualan made 351 million yuan of sales income, down 1.09 per cent year-on-year, and 120 million yuan net profit, up 52.2 per cent year-on-year. The shortage of plasma caused the insufficient of capacity utilization ratio was the main reason affected the slightly decline of the company’s operating income.
During 2005-2007, the sales proportion of human serum albumin of Hualan’s total sales gradually decreased from 79.8 per cent to 72.9 per cent and, 58.2 percent respectively, while IVIG sales rose rapidly from 8 per cent to 12 per cent and 26 per cent respectively; rest of other products accounted for the total sales increased rapidly from 20 per cent to 27 per cent and 42 per cent, contributing additional extra 51.14 million yuan sales in 2007. Meanwhile, the gross profit ratio of IVIG is higher than human serum albumin, which promoted Hualan's overall gross profit ratio rose sharply and profits increased significantly.
Customers who bought this item also bought
Hualan Biological Engineering,Inc.
China Vaccine Industry Report, 2008-2009
China Vaccine Industry Report, 2008-2009
China Company Research - Beijing Tiantan Biological Products Co., Ltd.
China Vaccine Market Report, 2007-2009
China Vaccine Market Report, 2007-2009
China Blood Products Industry Report, 2009
China Blood Products Industry Report, 2009
Research Report on China's Animal Vaccine Industry, 2009
Acquisition of 100 per cent of Sal. Oppenheim Group by Deutsche Bank AG Call - - Earnings Transcript
Analysis of Animal Vaccine Market in China 2009
Global Vaccine Market Forecast to 2012
|
|
|
|
